This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Incyte Reports 2012 Third-Quarter Financial Results; Updates Shareholders On Launch Of Jakafi And Lead Clinical Programs

Incyte Corporation (Nasdaq: INCY) today reported third-quarter 2012 financial results, including revenue from its first commercial product, Jakafi ® (ruxolitinib), which was approved by the U.S. Food & Drug Administration (FDA) for the treatment of patients with intermediate or high-risk myelofibrosis (MF) in November 2011. Novartis, the Company’s collaboration partner, announced that Jakafi, marketed as Jakavi ® outside the United States, received approval from the European Commission for the treatment of disease-related splenomegaly or symptoms in adult patients with primary MF, post-polycythemia vera MF or post-essential thrombocythemia MF. Jakafi/Jakavi is the first medicine to receive FDA and European Commission approval to treat patients with myelofibrosis and the first JAK inhibitor to be approved for any indication.

“We’re encouraged by the underlying demand for Jakafi, and we are building a strong foundation for long-term growth. With continued efforts to expand the use of Jakafi among new and existing prescribers, extensive educational efforts around the optimal use of Jakafi, and additional data being presented at the upcoming American Society of Hematology annual meeting, we’re confident that we will continue to see steady, consistent growth,” stated Paul A. Friedman, M.D., Incyte’s President and Chief Executive Officer.

2012 Third-Quarter Financial Results

Product Revenues

For the quarter and nine months ended September 30, 2012, net product revenues of Jakafi were $43.7 million and $92.7 million, respectively.

As expected, in the third quarter, the Company transitioned to the sell-in revenue recognition method from the sell-through method. Under the sell-in method, revenue is recognized when product is received by the specialty pharmacy, whereas under the sell-through method, revenue is recognized when the specialty pharmacy sends product to the patient, which reflects clinical demand. As a result, the $43.7 million of net product revenues for the third quarter of 2012 included $9.0 million of previously deferred revenue, representing product held by the specialty pharmacies at June 30, 2012.

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs